In patients with prolonged or profound neutropenia (absolute neutrophil count <500 cells/µL) or neutrophil dysfunction, what underlying conditions predispose them and which pathogens are most likely to cause infection?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Neutropenia and Neutrophil Dysfunction: Underlying Conditions and Associated Pathogens

Patients with prolonged or profound neutropenia (ANC <500 cells/µL) or neutrophil dysfunction are at highest risk for gram-negative bacterial infections (particularly Pseudomonas aeruginosa, Klebsiella pneumoniae, and E. coli), followed by gram-positive bacteria and invasive fungal infections (especially Aspergillus when neutropenia exceeds 7-10 days). 1, 2

Underlying Conditions That Cause Neutropenia or Neutrophil Dysfunction

Malignancy-Related Causes (Most Common)

  • Cytotoxic chemotherapy - the predominant cause of neutropenia in clinical practice 1
  • Hematologic malignancies:
    • Acute leukemia (particularly during induction/consolidation)
    • Acute myeloproliferative disorders
    • Myelodysplastic syndromes
    • Aplastic anemia
    • Chronic lymphocytic leukemia (CLL)
    • Lymphoma
    • Multiple myeloma 1, 3

Immunosuppressive Therapies

  • Alemtuzumab therapy - high-risk category 1
  • Purine analog therapy (fludarabine, clofarabine, nelarabine, cladribine) - intermediate to high risk 1
  • CAR T-cell therapy - intermediate risk 1
  • Hematopoietic stem cell transplantation:
    • Allogeneic HCT (highest risk, especially cord blood)
    • Autologous HCT (intermediate risk) 1, 3
  • Graft-versus-host disease (GVHD) requiring intensive immunosuppressive therapy 1

Drug-Induced Neutropenia

  • Azathioprine
  • Mycophenolate mofetil
  • Vancomycin
  • Beta-lactam antibiotics
  • Sulfonamides
  • Ganciclovir 4, 5

Congenital Neutrophil Disorders

  • Cyclic neutropenia
  • Chronic granulomatous disease
  • Job syndrome (Hyper-IgE syndrome)
  • Severe congenital neutropenia (mutations in ELANE, HAX1, SBDS genes) 6, 7

Other Causes

  • Marrow infiltrative disorders
  • Connective tissue disorders (autoimmune neutropenia)
  • Overwhelming sepsis
  • Nutritional deficiencies 7, 4

Pathogen Risk Stratification by Duration and Severity

Bacterial Pathogens (All Durations of Neutropenia)

Gram-negative bacteria predominate in neutropenic patients (70.4% vs. 55.0% in non-neutropenic patients) 2:

  • Most common: Pseudomonas aeruginosa (leading pathogen)
  • Followed by: Klebsiella pneumoniae, Escherichia coli
  • Also significant: Acinetobacter baumannii, Stenotrophomonas maltophilia 2

Critical caveat: E. coli and K. pneumoniae from neutropenic patients produce extended-spectrum β-lactamases (ESBLs) at significantly higher rates than from non-neutropenic patients (E. coli: 57.6% vs. 30.3%; K. pneumoniae: 31.9% vs. 13.0%) 2. This has major implications for empiric antibiotic selection.

Gram-positive bacteria also cause significant infections:

  • Coagulase-negative staphylococci
  • Staphylococcus aureus (particularly in skin/soft tissue infections) 8, 9

In bloodstream infections from neutropenic patients: Gram-negative bacilli account for 58.2% of isolates (excluding coagulase-negative staphylococci) 2.

Fungal Pathogens (Prolonged Neutropenia >7-10 Days)

Invasive fungal disease risk increases dramatically with neutropenia duration >7 days 1:

  • Invasive aspergillosis - the primary mold concern, particularly when neutropenia exceeds 10 days or in patients with chronic severe neutropenia (ANC <500) 1, 10
  • Candida species - invasive candidiasis and chronic disseminated candidiasis 1, 8

The risk threshold for invasive aspergillosis exceeds 6% in:

  • Acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS) patients
  • Patients receiving treatment for GVHD 3

Viral Pathogens

Herpes simplex virus (HSV) reactivation occurs in 60-80% of seropositive patients undergoing:

  • Hematopoietic cell transplantation
  • Acute leukemia induction/reinduction therapy (without prophylaxis) 1

Other viral considerations:

  • Hepatitis B virus (HBV) reactivation in at-risk patients
  • Influenza (vaccination recommended for patients and contacts) 3

Risk-Based Prophylaxis Algorithm

High-Risk Patients (Neutropenia Expected >10 Days)

Examples: Allogeneic HCT, acute leukemia induction/consolidation, alemtuzumab therapy, moderate-to-severe GVHD 1

  • Antibacterial: Fluoroquinolone prophylaxis (levofloxacin preferred) during neutropenia 1, 3
  • Antifungal: Mold-active triazole (posaconazole preferred, category 1 evidence) or echinocandin during neutropenia; continue until ANC >500 or at least day 75 post-allogeneic HCT 1
  • Antiviral: HSV prophylaxis with nucleoside analog (acyclovir) until WBC recovery or mucositis resolution 1, 3
  • PCP prophylaxis: Consider trimethoprim-sulfamethoxazole 1

Intermediate-Risk Patients (Neutropenia Expected 7-10 Days)

Examples: Autologous HCT, lymphoma, multiple myeloma, CLL, purine analog therapy, CAR T-cell therapy 1

  • Antibacterial: Consider fluoroquinolone prophylaxis during neutropenia 1, 3
  • Antifungal: Consider prophylaxis during neutropenia and anticipated mucositis; consider PCP prophylaxis 1
  • Antiviral: During neutropenia and longer depending on risk 1

Low-Risk Patients (Neutropenia Expected <7 Days)

Examples: Standard chemotherapy for most solid tumors 1

  • No routine antibacterial prophylaxis recommended - the main benefit would be fever reduction rather than prevention of documented infections 1, 3
  • No routine antifungal prophylaxis 1
  • Antiviral: Only if prior HSV episode 1

Critical Clinical Pitfalls

  1. Duration matters more than depth for fungal risk: Neutropenia lasting >7 days dramatically increases invasive aspergillosis risk, regardless of how low the ANC drops 1, 10

  2. Non-fermentative gram-negative bacilli are disproportionately common: These organisms (Pseudomonas, Acinetobacter, Stenotrophomonas) account for 52.9% of isolates in neutropenic patients vs. 30.5% in non-neutropenic patients 2

  3. Respiratory specimens show even higher gram-negative predominance: 79.1% in neutropenic vs. 56.1% in non-neutropenic patients 2

  4. ESBL-producing organisms are the rule, not the exception: Over half of E. coli and nearly one-third of K. pneumoniae from neutropenic patients produce ESBLs 2

  5. Neutrophil dysfunction syndromes carry similar infection risks: Chronic granulomatous disease and other functional defects predispose to S. aureus, gram-negative bacilli, and Candida infections even with normal neutrophil counts 9

  6. Secondary prophylaxis is mandatory: Patients with prior invasive fungal infections require mold-active prophylaxis during all subsequent immunosuppression periods 1

References

2
Research

Bacterial Pathogens Differed Between Neutropenic and Non-neutropenic Patients in the Same Hematological Ward: An 8-Year Survey.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2018

4
Research

Secondary Neutropenias.

Biomedicines, 2025

6
Research

How to approach neutropenia.

Hematology. American Society of Hematology. Education Program, 2012

7
Research

Diagnosis and management of neutropenia.

Blood research, 2025

8
Research

Infections in neutropenic patients I: aetiology.

Medical oncology (Northwood, London, England), 1995

9
Research

Neutrophil function disorders.

Disease-a-month : DM, 1987

10
Research

[Pneumonia in the immunocompromised patient].

La Revue du praticien, 2011

Related Questions

What is the appropriate diagnostic workup and management for neutropenia?
How should a patient with a white blood cell count of 2.4 ×10⁹/L and an absolute neutrophil count of 0.5 ×10⁹/L be managed?
What does an absolute neutrophil count of 493 cells/µL indicate and how should it be managed?
What are the neutropenia grades based on absolute neutrophil count and how should neutropenia be managed in patients receiving acalabrutinib?
What are the causes of neutropenia?
What is the appropriate evaluation and management for a 51‑year‑old patient with diabetes mellitus who has had diffuse bruising of the trunk, limbs, and back for several months?
What are the indications, dosing regimen, monitoring requirements, and contraindications for using tofacitinib in a patient with ankylosing spondylitis?
What prognostic scoring system should be used for myelodysplastic syndrome (MDS) instead of an MDS International Prognostic Index (IPI)?
What is the most appropriate first-line oral antibiotic for an infected foot wound following a pedicure?
In patients with peripheral spondyloarthritis, when is tofacitinib indicated, and what are the recommended dose, monitoring parameters, contraindications, and alternative treatment options?
How is the risk of kidney transplant rejection assessed?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.